Eli Lilly and Company (LLY)

Working capital turnover

Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Revenue US$ in thousands 45,042,700 34,124,100 28,541,400 28,318,400 24,539,800
Total current assets US$ in thousands 32,739,700 25,727,000 18,034,500 18,452,400 17,462,100
Total current liabilities US$ in thousands 28,376,600 27,293,200 17,138,200 15,052,700 12,481,600
Working capital turnover 10.32 31.84 8.33 4.93

December 31, 2024 calculation

Working capital turnover = Revenue ÷ (Total current assets – Total current liabilities)
= $45,042,700K ÷ ($32,739,700K – $28,376,600K)
= 10.32

The working capital turnover ratio for Eli Lilly and Company has shown significant improvement over the years. In December 31, 2020, the ratio stood at 4.93, indicating that the company generated approximately $4.93 of revenue for every $1 of working capital. By December 31, 2021, the ratio increased to 8.33, suggesting the company became more efficient in utilizing its working capital to generate sales.

The most notable improvement came in December 31, 2022, where the working capital turnover ratio surged to 31.84, reflecting a substantial increase in revenue generation relative to the working capital invested. This sharp rise suggests enhanced operational efficiency, effective management of inventory, receivables, and payables, or possibly a strategic shift in business operations.

Unfortunately, data for December 31, 2023, is unavailable (displayed as "—"), potentially due to reporting delays or alterations in disclosure practices. Nevertheless, the previous trend indicates a strong focus on maximizing revenue from working capital.

The working capital turnover ratio decreased slightly to 10.32 by December 31, 2024, but it remains relatively high compared to the initial values. This suggests that Eli Lilly and Company continues to effectively leverage its working capital resources to drive sales. Overall, the improving trend in the working capital turnover ratio underscores the company's efficient management of working capital and its ability to generate revenue efficiently.


See also:

Eli Lilly and Company Working Capital Turnover